# Next-Generation Antioxidants in Cardiovascular Disease: Mechanistic Insights and Emerging Therapeutic Strategies

**Authors:** Desh Deepak Singh, Dharmendra Kumar Yadav, Dongyun Shin

PMC · DOI: 10.3390/antiox15020164 · Antioxidants · 2026-01-25

## TL;DR

This review explores new antioxidant therapies for cardiovascular disease, highlighting how recent scientific advances could lead to more effective treatments.

## Contribution

The paper introduces next-generation antioxidant strategies based on recent advancements in redox biology and nanotechnology.

## Key findings

- Traditional antioxidants like vitamins C and E have failed to show clinical benefits in human trials.
- New antioxidant approaches include mitochondrial-targeted agents, NOX inhibitors, and gene-editing strategies.
- These novel therapies aim to modulate specific oxidative pathways involved in cardiovascular disease.

## Abstract

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide. CVDs are associated with multiple factors, including oxidative stress, mediated endothelial dysfunction, vascular inflammation, and atherothrombosis. Although traditional antioxidant supplementation (such as vitamins C, E, and β-carotene) has shown promising results in rigorous animal model studies, it has consistently failed to demonstrate clinical benefit in most human trials. Consequently, there is a substantial unmet need for novel paradigms involving mechanistically and biologically relevant pharmaceutical-grade antioxidant therapies (“next-generation antioxidants”). Rapid advancements in redox biology, nanotechnology, genetic modulation of redox processes, and metabolic regulation have enabled the development of new antioxidant therapeutics, including mitochondrial-targeted agents, NADPH oxidase (NOX) inhibitors, selenoprotein and Nrf2 activators, engineered nanoparticles, catalytic antioxidants, and RNA-based and gene-editing strategies. These interventions have the potential to modulate specific oxidative pathways that contribute to CVD pathogenesis. This review provides a comprehensive assessment of current oxidative stress–modulating modalities and their potential to inform personalized cardiovascular prevention and treatment strategies.

## Linked entities

- **Proteins:** Nox (NADPH oxidase), GABPA (GA binding protein transcription factor subunit alpha)
- **Chemicals:** vitamin C (PubChem CID 54670067), vitamin E (PubChem CID 14985), β-carotene (PubChem CID 573)

## Full-text entities

- **Genes:** NCF1 (neutrophil cytosolic factor 1) [NCBI Gene 653361] {aka CGD1, NCF-1, NCF-47K, NCF1A, NOXO2, SH3PXD1A}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, NOX1 (NADPH oxidase 1) [NCBI Gene 27035] {aka GP91-2, MOX1, NOH-1, NOH-1L, NOH1}, PRKG1 (protein kinase cGMP-dependent 1) [NCBI Gene 5592] {aka AAT8, PKG, PKG1, PRKG1B, PRKGR1B, cGK}, SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, CAT (catalase) [NCBI Gene 847], MPO (myeloperoxidase) [NCBI Gene 4353], NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, GPX1 (glutathione peroxidase 1) [NCBI Gene 2876] {aka GPXD, GSHPX1}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, NOX4 (NADPH oxidase 4) [NCBI Gene 50507] {aka KOX, KOX-1, RENOX}, CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536] {aka AMCBX2, CGD, CGDX, GP91-1, GP91-PHOX, GP91PHOX}, NQO1 (NAD(P)H quinone dehydrogenase 1) [NCBI Gene 1728] {aka DHQU, DIA4, DTD, NMOR1, NMORI, QR1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, HSD17B6 (hydroxysteroid 17-beta dehydrogenase 6) [NCBI Gene 8630] {aka HSE, RODH, SDR9C6}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, SLC8A1 (solute carrier family 8 member A1) [NCBI Gene 6546] {aka NCX1}, NOX5 (NADPH oxidase 5) [NCBI Gene 79400]
- **Diseases:** reperfusion injury (MESH:D015427), thrombosis (MESH:D013927), death (MESH:D003643), hypertension (MESH:D006973), diabetic cardiomyopathy (MESH:D058065), atherogenesis (MESH:D050197), dilation (MESH:D002311), coagulation (MESH:D001778), CVD (MESH:D002318), myocardial infarctions (MESH:D009203), myocardial hypertrophy (MESH:D006984), ischemic heart disease (MESH:D017202), vascular (MESH:D057772), vascular dysfunction (MESH:D002561), age-related diseases (MESH:D010024), peripheral arterial disease (MESH:D058729), type 2 diabetes (MESH:D003924), Heart Failure (MESH:D006333), hypercholesterolemia (MESH:D006937), Myocardial Dysfunction (MESH:D006331), primary biliary cholangitis (MESH:D008105), atherosclerotic plaques (MESH:D058226), endothelial (MESH:D005642), HFpEF (MESH:D054144), chronic disease (MESH:D002908), chronic inflammation (MESH:D007249), neurodegenerative disease (MESH:D019636), injury (MESH:D014947), cardiometabolic disorders (MESH:D024821), hyperlipidemia (MESH:D006949), cardiomyocyte loss (MESH:D016388), and vascular fibrosis (MESH:D005355), fluid (MESH:D002559), Mitochondrial (MESH:D028361), mitochondrial myopathy (MESH:D017240), acute coronary syndromes (MESH:D054058), NAFLD (MESH:D065626), lung cancer (MESH:D008175), Cancer (MESH:D009369), diabetes (MESH:D003920), atherosclerotic plaque rupture (MESH:D012421), ischemic (MESH:D002545), Endothelial Dysfunction (MESH:D014652), hemorrhagic strokes (MESH:D000083302), chronic kidney disease (MESH:D051436), left ventricular stroke (MESH:D018487), obesity (MESH:D009765), diabetic vascular disease (MESH:D003925), myocardial damage (MESH:D009202), stroke (MESH:D020521), metabolic disease (MESH:D008659), ischemia (MESH:D007511)
- **Chemicals:** MTAs (-), Superoxide (MESH:D013481), hydrogen peroxide (MESH:D006861), plastoquinone (MESH:D010971), bardoxolone methyl (MESH:C445068), BH4 (MESH:C003402), asbestos (MESH:D001194), 8-iso-PGF2alpha (MESH:C075750), fatty acid (MESH:D005227), Dimethyl fumarate (MESH:D000069462), Polyphenols (MESH:D059808), ATP (MESH:D000255), peroxynitrite (MESH:D030421), glutathione (MESH:D005978), lipid (MESH:D008055), beta-Carotene (MESH:D019207), Alpha-tocopherol (MESH:D024502), purine (MESH:C030985), ubiquinone (MESH:D014451), RNS (MESH:D011886), ADMA (MESH:C018524), glucose (MESH:D005947), calcium (MESH:D002118), ROS (MESH:D017382), Elamipretide (MESH:C506540), cGMP (MESH:D006152), GKT137831 (MESH:C576694), oxygen (MESH:D010100), TPP+ (MESH:C016136), Vitamin E (MESH:D014810), hypochlorous acid (MESH:D006997), ketone (MESH:D007659), sulforaphane (MESH:C016766), bardoxolone (MESH:C000718175), cardiolipin (MESH:D002308), MitoQ (MESH:C429014), prostacyclin (MESH:D011464), Vitamin C (MESH:D001205), NO (MESH:D009569), cholesterol (MESH:D002784)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** vascular smooth muscle — Homo sapiens (Human), Finite cell line (CVCL_4009)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938358/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938358/full.md

## References

192 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938358/full.md

---
Source: https://tomesphere.com/paper/PMC12938358